Abstract
The Harmony transcatheter pulmonary valve (TPV) is designed to treat severe pulmonary regurgitation (PR) in the native or surgically repaired right ventricular outflow tract (RVOT). Our objective was to evaluate 1-year safety and effectiveness in patients from the Early Feasibility Study (EFS), Harmony TPV Pivotal Study, and Continued Access Study (CAS), representing the largest cohort to date of Harmony TPV recipients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Journal of the Society for Cardiovascular Angiography & Interventions
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.